Home / Resource Library / Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell LymphomaOutcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma ASH 2020: Study examined outcomes of patients with mantle cell lymphoma who relapse while on treatment with Acalabrutinib.